> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Glaxo Myeloma Therapy
- URL: https://www.fdaweb.com/fda-oks-glaxo-myeloma-therapy/
- Published: 2020-08-06T12:00:00.000Z
- Updated: 2026-09-14T16:24:10.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147372

FDA has granted GlaxoSmithKline accelerated approval for Blenrep (belantamab mafodotin-blmf) for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Approval was based on data from the DREAMM-2, an open-label, multicenter trial. The overall response rate was 31%, and 73% of responders had response durations greater than six months, according to an FDA [news release](http://s2027422842.t.en25.com/e/es?s=2027422842&e=360420&elqTrackId=376c7bc788024cd5a73d955f2e3dcbdc&elq=16a85249f9ca4b51a2905194ff4fdaad&elqaid=13686&elqat=1&ref=fdaweb.com). The prescribing information includes a Boxed Warning about the therapy causing changes in the corneal epithelium resulting in alterations in vision, including severe vision loss and corneal ulcer, and symptoms, such as blurred vision and dry eyes.